SP Group (SPG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
30 Apr, 2026Executive summary
Achieved record Q1 2026 results with revenue up 22.9% year-over-year to DKK 966 million, including 11.3% organic growth and 11.6% from the Idé-Pro acquisition.
EBITDA increased 18.5% to DKK 197 million, with all product groups reporting higher sales.
Strong growth in both own products (+4.1%) and subsupplier projects (+30.5%) compared to Q1 2025.
Integration of Idé-Pro progressing as planned, with cross-selling underway and expansion plans in India.
Expansion of Healthcare production in Poland and operational launch of Stourup solar park.
Financial highlights
Revenue reached DKK 966 million (+22.9% YoY); EBITDA: DKK 197 million (+18.5% YoY, margin 20.4%).
EBIT: DKK 139.5 million (+19.1% YoY, margin 14.4%); EBT: DKK 126 million (+24.2% YoY, margin 13.0%).
Net profit: DKK 99.2 million (+25.1% YoY); diluted EPS up 28.6% to DKK 8.4.
Cash flow from operations: DKK 159 million (+21.9% YoY); net interest-bearing debt reduced by DKK 72 million to DKK 1,388 million.
Equity increased by DKK 56 million to DKK 1,865 million; solvency ratio at 45.5%.
Outlook and guidance
FY 2026 guidance maintained: revenue growth of 15–23% (DKK 3.4–3.6 billion), EBITDA margin 19–21%, EBT margin 11–13%.
Idé-Pro expected to contribute about 15% of full-year revenue.
Growth expected from new products, customers, and Idé-Pro acquisition; outlook assumes normalization of geopolitical conditions.
Latest events from SP Group
- Record Q1 2026 growth, robust outlook, and active capital returns amid global uncertainty.SPG
Q1 202630 Apr 2026 - Record Q4 and Idé-Pro acquisition set stage for strong 2026 growth amid ongoing uncertainties.SPG
Q4 202525 Mar 2026 - Record Q4 and strong 2026 growth outlook, boosted by Idé-Pro acquisition.SPG
Q4 202525 Mar 2026 - Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 202423 Jan 2026 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 202426 Dec 2025 - Acquisition enables in-house toolmaking, new materials, and DKK 20–25m annual synergies.SPG
M&A Announcement19 Dec 2025 - Record Q1 growth and margin gains led by Healthcare; outlook steady amid global risks.SPG
Q1 202524 Nov 2025 - Q2 slowdown led to lower H1 results and a flat outlook, but margins and investments remain strong.SPG
Q2 202523 Nov 2025 - 2025 guidance maintained as order backlog and new projects offset lower sales and margins.SPG
Q3 202520 Nov 2025